Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.
IPO Year:
Exchange: NASDAQ
Website: dyadic.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/18/2022 | Buy → Neutral | Dawson James | |
| 12/17/2021 | $7.00 | Buy | HC Wainwright & Co. |
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560
JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C. World Vaccine Congress | Washington, D.C.April 22–24, 2025Presentation: Wednesday, April 23, 2025 | 12:40
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20
JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it has received a funding award from CEPI to use C1 to accelerate the development of protein-based vaccines. CEPI is providing US$4.5 million to non-profit Fondazione Biotecnopolo di Siena (FBS) for proof-of-concept research that will explore whether producing antigens in C1 filamentous fungus—applying tec
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the year ended 2024 and host a corporate update conference call on Wednesday, March 26, 2025. Conference Call Information Date: Wednesday, March 26, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-85
JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced its management's participation in several prominent industry events worldwide. World AGRI-Tech Innovation Summit March 11-12, 2025San Francisco, CA Future Food-TechMarch 13–14, 2025San Francisco, CADyadic Booth No: #2 Microbial Engineering III: New Generation of Cell Factory to Meet the Future Challeng
JUPITER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, provided an update on its business development efforts related to its Alternative Proteins business and emerging interest in leveraging the C1 platform in the diagnostic and vaccine space to address a variety of infectious diseases, such as the H5N1 Avian Influenza ("Bird Flu") outbreak. The Company also announced its at
JUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI), a global biotechnology company, announced today that it has been awarded a $3 million grant from the Gates Foundation for the cell line development of monoclonal antibodies (mAbs) targeting respiratory syncytial virus (RSV) and malaria utilizing the company's proprietary C1 protein production platform to provide globally accessible treatment options for underserved populations. RSV is a major cause of lower respiratory tract infection morbidity and mortality in children globally, causing 3.2–36 million hospitalizations and more than 100,000 deaths annually, 99% of which occur in low-income and middl
Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license fees and milestone payments.Received $1 million milestone payment for animal-free recombinant albumin products.Received $425,000 success fees for achieving production targets in a dairy enzyme collaboration.Expanded recombinant life science protein portfolio within six additional products in development for molecular biology and cell culture media applications. Human Health Co-developed a highly productive C1-produced ferritin nanoparticle Mpox (mo
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the third quarter 2024 and host a corporate update conference call on Tuesday, November 12, 2024. Conference Call Information: Date: Tuesday, November 12, 2024Time: 5:00 p.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560Conference
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
DEFA14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)
DEF 14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
EFFECT - DYADIC INTERNATIONAL INC (0001213809) (Filer)
S-3 - DYADIC INTERNATIONAL INC (0001213809) (Filer)
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
10-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
Dawson James downgraded Dyadic International from Buy to Neutral
HC Wainwright & Co. initiated coverage of Dyadic International with a rating of Buy and set a new price target of $7.00
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the year ended 2024 and host a corporate update conference call on Wednesday, March 26, 2025. Conference Call Information Date: Wednesday, March 26, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-85
Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license fees and milestone payments.Received $1 million milestone payment for animal-free recombinant albumin products.Received $425,000 success fees for achieving production targets in a dairy enzyme collaboration.Expanded recombinant life science protein portfolio within six additional products in development for molecular biology and cell culture media applications. Human Health Co-developed a highly productive C1-produced ferritin nanoparticle Mpox (mo
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the third quarter 2024 and host a corporate update conference call on Tuesday, November 12, 2024. Conference Call Information: Date: Tuesday, November 12, 2024Time: 5:00 p.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560Conference
Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint development agreement with a Top 10 global dairy company for the development of non-animal alpha-lactalbuminOngoing development of a robust pipeline of non-pharmaceutical recombinant product candidates such as alpha-lactalbumin, transferrin, DNASE-1, and several potential biofuels and other enzymes utilizing the Dapibus™ platform technology Animal Health Provided samples of the C1-produced recombinant ferritin nanoparticle H5 Clade 2.3.3.4.b A/Astrakhan avian influenza ‘Bird Flu' antigen to multi
JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the second quarter 2024 and host a corporate update conference call on Tuesday, August 13, 2024. Conference Call Information: Date: Tuesday, August 13, 2024 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560 Confere
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against COVID-19 infectionEntered into several fully funded vaccine and antibody projects covering more than twelve targets, five of which are funded by two of the top ten pharmaceutical companiesSuccessfully expressed a H1N1 influenza antigen in our collaboration with the Vaccine and Immunotherapy Center ("VIC") at Massachusetts General HospitalAnnounced strategic partnership to develop affordable rabies prophylactics and vaccin
JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the first quarter 2024 and host a corporate update conference call on Tuesday, May 14, 2024. Conference Call Information: Date: Tuesday, May 14, 2024 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560 Conference ID
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein receptor binding domain (RBD) booster vaccine candidate for protection against COVID-19 infection Entered into several fully funded vaccine and antibody projects covering more than twelve targets since announcing topline clinical safety data from First-In-Human Phase 1 trial Executed a term sheet to utilize our microbial protein production platforms to develop production strains for the production of recombinant serum albumin initiall
JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and
JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company's new and existing business initiatives, including corporate strategy, business and corporate develo
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G - DYADIC INTERNATIONAL INC (0001213809) (Subject)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)